AZD1222 US Phase III trial met primary efficacy endpoint in preventing COVID-19 at interim analysis

This analysis validates the AstraZeneca COVID-19 vaccine as a much-needed additional vaccination option, offering confidence that adults of all ages … Read more at www.astrazeneca.com

NAME Group